Covishield vaccine demonstrated more robust immune response compared to Covaxin: Study

Covishield leveraged a virus vector to deliver the spike protein of the coronavirus

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru

A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences (NCBS), has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin.

(For top health news of the day, subscribe to our newsletter Health Matters)

The study compared the immunogenicity of Covishield and Covaxin, the two primary COVID-19 vaccines widely used in India.

The findings of the study, which have been published in the journal The Lancet Regional Health Southeast Asia, offer valuable insights into the quality and quantity of immune responses induced by these vaccines against SARS-CoV-2, with significant implications for shaping future vaccination strategies.

The key findings state that Covishield, leveraging a virus vector to deliver the spike protein of the coronavirus, consistently demonstrated more robust immune response compared to Covaxin, an inactivated virus vaccine.

“Notably, Covishield exhibited a near-complete immune response in the majority of participants, whereas the response to Covaxin was variable, particularly among those inoculated before the emergence of the omicron variant,” states the key findings released by NCBS.

The study, carried out from June 2021 to January 2022, involved assessing 691 participants, aged between 18 and 45 years, from Bengaluru and Pune.

It examined their vaccination records and monitored their immune responses at different intervals, both prior to and following vaccination.

Covishield elicited more T cells indicative of stronger immune response

Further, according to the key finding, Covishield induced higher antibody levels in both seronegative (individuals without prior exposure) and seropositive (individuals with prior exposure) subjects, suggesting a more potent and enduring immune response.

Covishield elicited a higher number of T cells compared to Covaxin, indicative of a stronger immune response.

According to the findings: “Covishield consistently exhibited higher level of antibodies against various virus strains compared to Covaxin, suggesting its potential superior protection against variants such as omicron”.

“Follow-up studies on vaccine immunology and the analysis of immune protection factors were lacking and, there’s a scarcity of comparative studies on these two vaccines. This is one of the very few studies that not only investigates the immune responses of participants after vaccination, but also considers their immune history prior to vaccination,” said Dr. Mangaiarkarasi Asokan, former programme head, VISION (Vaccine Immunology Studies-Indian Outbreak-response Network) and lead author of the study.

Prof. Satyajit Mayor, scientist, NCBS-TIFR, said that this study was done at the height of the Covid pandemic and reflected a collective sentiment to bring evidence-based decision-making to the outcomes of vaccination in the Indian population, using two indigenous vaccines that were rolled out very quickly for the Indian population.

Lessons for future strategies

“The creation of a bio-repository from the 15-month longitudinal study is invaluable. Analysis of the data and exploring the collected bio-resources will inform future immunisations strategies, at least for Covid. Finally, the outcome of the study where the Covishield vaccine was shown to outperform Covaxin in all respects, should have important implications to strategise future vaccination drives,” Prof. Mayor said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.